FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1231-1242 March 23, 2006 Number 12 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Rubinow, D. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.

Methods We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology — Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores).

Results Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.

Conclusions After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528 [ClinicalTrials.gov] .)

Source Information

From the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (A.J.R., M.H.T., M.M.B., D.W., K.S.-W.); the Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh (S.R.W., J.F.L.), and the Department of Psychiatry, University of Pittsburgh School of Medicine (M.E.T.) — both in Pittsburgh; the New York State Psychiatric Institute and Columbia College of Physicians and Surgeons, New York (J.W.S.); the Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston (A.A.N., M.F.); and the National Institute of Mental Health, Bethesda, Md. (L.R., G.N.).

Address reprint requests to Dr. Rush at the Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9086, or at john.rush{at}utsouthwestern.edu.

Full Text of this Article

Related Letters:

Depression — Augmentation or Switch after Initial SSRI Treatment
Sussman N., Williams S. C., Tebartz van Elst L., Ebert D., Hesslinger B., Rush A. J., Trivedi M. H., Wisniewski S. R., the STAR*D trial investigators , Rubinow D. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2611-2613, Jun 15, 2006. Correspondence

This article has been cited by other articles:

• Rush, A. J. MD (2008). Developing the evidence for evidence-based practice. CMAJ 178: 1313-1315 [Full Text]  
• Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., Warden, D., Trivedi, M. H. (2008). Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. Am. J. Psychiatry 165: 342-351 [Abstract] [Full Text]  
• Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., Birmaher, B., Ryan, N., Kennard, B., Hughes, C., DeBar, L., McCracken, J., Strober, M., Suddath, R., Spirito, A., Leonard, H., Melhem, N., Porta, G., Onorato, M., Zelazny, J. (2008). Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial. JAMA 299: 901-913 [Abstract] [Full Text]  
• Clayton, P., Auster, T. (2008). Strategies for the Prevention and Treatment of Suicidal Behavior. Focus 6: 15-21 [Abstract] [Full Text]  
• (2008). Bibliography for Major Depressive Disorder and Suicide. Focus 6: 58-62 [Full Text]  
• Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., Niederehe, G., Hollon, S. D., Rush, A. J. (2008). Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Focus 6: 104-119 [Abstract] [Full Text]  
• Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., Fava, M. (2008). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Focus 6: 128-142 [Abstract] [Full Text]  
• Aikens, J. E., Nease, D. E. Jr, Klinkman, M. S. (2008). Explaining Patients' Beliefs About the Necessity and Harmfulness of Antidepressants. Ann Fam Med 6: 23-29 [Abstract] [Full Text]  
• Unutzer, J. (2007). Late-Life Depression. NEJM 357: 2269-2276 [Full Text]  
• Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., Gharabawi-Garibaldi, G. M. (2007). Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial. ANN INTERN MED 147: 593-602 [Abstract] [Full Text]  
• Tinklenberg, J. R., Kraemer, H. C., Yaffe, K., Ross, L., Sheikh, J., Ashford, J. W., Yesavage, J. A., Taylor, J. L. (2007). Donepezil Treatment and Alzheimer Disease: Can the Results of Randomized Clinical Trials Be Applied to Alzheimer Disease Patients in Clinical Practice?. AJGP 15: 953-960 [Abstract] [Full Text]  
• Haddad, P. M., Anderson, I. M. (2007). Recognising and managing antidepressant discontinuation symptoms. Adv. Psychiatr. Treat. 13: 447-457 [Abstract] [Full Text]  
• Fink, M., Taylor, M. A. (2007). Electroconvulsive Therapy: Evidence and Challenges. JAMA 298: 330-332 [Full Text]  
• Lesperance, F., Frasure-Smith, N. (2007). Treatment of Depression in Patients With Coronary Artery Disease--Reply. JAMA 297: 1880-1880 [Full Text]  
• Weissman, M. M. (2007). Cognitive Therapy and Interpersonal Psychotherapy: 30 Years Later. Am. J. Psychiatry 164: 693-696 [Full Text]  
• Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., Niederehe, G., Hollon, S. D., Rush, A. J. (2007). Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Am. J. Psychiatry 164: 739-752 [Abstract] [Full Text]  
• Schramm, E., van Calker, D., Dykierek, P., Lieb, K., Kech, S., Zobel, I., Leonhart, R., Berger, M. (2007). An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Depressed Inpatients: Acute and Long-Term Results. Am. J. Psychiatry 164: 768-777 [Abstract] [Full Text]  
• Barondes, S. H. (2007). Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness. NEJM 356: 646-647 [Full Text]  
• Rubino, A., Roskell, N., Tennis, P., Mines, D., Weich, S., Andrews, E. (2007). Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334: 242-242 [Abstract] [Full Text]  
• Ehret, M. J., Chavez, B. (2006). A Review of the STAR*D Trial. Journal of Pharmacy Practice 19: 353-360 [Abstract]  
• Nelson, J. C. (2006). The STAR*D Study: A Four-Course Meal That Leaves Us Wanting More. Am. J. Psychiatry 163: 1864-1866 [Full Text]  
• Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., Fava, M. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am. J. Psychiatry 163: 1905-1917 [Abstract] [Full Text]  
• Papakostas, G. I (2006). Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram.. Evid. Based Ment. Health 9: 100-100 [Full Text]  
• Zisook, S. (2006). Ask the Expert PSYCHOPHARMACOLOGY: MAJOR DEPRESSIVE DISORDER. Focus 4: 484- [Full Text]  
• Valenstein, M. (2006). Keeping Our Eyes on STAR{star}D. Focus 4: 522- [Full Text]  
• Menza, M. (2006). STAR{star}D: The Results Begin to Roll in. Focus 4: 525- [Full Text]  
• Valenstein, M. (2006). Keeping Our Eyes on STAR*D. Am. J. Psychiatry 163: 1484-1486 [Full Text]  
• Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., Lebowitz, B., Shores-Wilson, K., Rush, A. J., STAR*D Study Team, (2006). A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. Am. J. Psychiatry 163: 1519-1530 [Abstract] [Full Text]  
• McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., Luther, J. F., Niederehe, G., Warden, D., Rush, A. J., STAR*D Study Team, (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am. J. Psychiatry 163: 1531-1541 [Abstract] [Full Text]  
• Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., Sajatovic, M., and Coauthors for the Cooperative Studies Program, (2006). Collaborative Care for Bipolar Disorder: Part I. Intervention and Implementation in a Randomized Effectiveness Trial. Psychiatr. Serv. 57: 927-936 [Abstract] [Full Text]  
• Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., Sajatovic, M., and Coauthors for the Cooperative Studies Program, (2006). Collaborative Care for Bipolar Disorder: Part II. Impact on Clinical Outcome, Function, and Costs. Psychiatr. Serv. 57: 937-945 [Abstract] [Full Text]  
• Menza, M. (2006). STAR*D: The Results Begin to Roll in. Am. J. Psychiatry 163: 1123-1123 [Full Text]  
• Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., Niederehe, G., Ritz, L., Trivedi, M. H., STAR*D StudyTeam, (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. Am. J. Psychiatry 163: 1161-1172 [Abstract] [Full Text]  
• Sussman, N., Williams, S. C., Tebartz van Elst, L., Ebert, D., Hesslinger, B., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., the STAR*D trial investigators, , Rubinow, D. R. (2006). Depression--augmentation or switch after initial SSRI treatment.. NEJM 354: 2611-2613 [Full Text]  
• (2006). Multiple Levels of Drug Treatment for Depression. Journal Watch Dermatology 2006: 9-9 [Full Text]  
• (2006). When an SSRI Fails. JWatch Women's Health 2006: 8-8 [Full Text]  
• (2006). Multiple Levels of Drug Treatment for Depression. JWatch General 2006: 5-5 [Full Text]  
• (2006). What to Do After Depressed Patients Fail an SSRI. JWatch Psychiatry 2006: 1-1 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals.. BMJ 332: 781-782 [Full Text]  
• Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., Luther, J. F., Shores-Wilson, K., Rush, A. J., the STAR*D Study Team, (2006). Medication augmentation after the failure of SSRIs for depression.. NEJM 354: 1243-1252 [Abstract] [Full Text]  
• Rubinow, D. R. (2006). Treatment strategies after SSRI failure--good news and bad news.. NEJM 354: 1305-1307 [Full Text]